Trial data showed the new vaccine, developed by GlaxoSmithKline, was 82% effective at preventing lower respiratory tract illness caused by RSV.
from USATODAY - News Top Stories
https://ift.tt/EyNJqtV
May 03, 2023 at 11:29PM
Trial data showed the new vaccine, developed by GlaxoSmithKline, was 82% effective at preventing lower respiratory tract illness caused by RSV.
0 Comments